Fulgent Genetics Analyst Ratings
Fulgent Genetics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/08/2022 | 7.9% | Piper Sandler | $65 → $40 | Downgrades | Overweight → Neutral |
| 11/18/2022 | 21.39% | Raymond James | → $45 | Initiates Coverage On | → Outperform |
| 11/14/2022 | 34.88% | Credit Suisse | $65 → $50 | Maintains | Outperform |
| 11/14/2022 | 75.34% | Piper Sandler | $70 → $65 | Maintains | Overweight |
| 08/25/2022 | 75.34% | Credit Suisse | → $65 | Initiates Coverage On | → Outperform |
| 05/16/2022 | 88.83% | Piper Sandler | $85 → $70 | Maintains | Overweight |
| 01/25/2022 | 237.2% | Oppenheimer | $141 → $125 | Maintains | Outperform |
| 08/10/2021 | 75.34% | Credit Suisse | $55 → $65 | Maintains | Underperform |
| 03/05/2021 | 277.66% | Piper Sandler | $135 → $140 | Maintains | Overweight |
| 02/01/2021 | 250.69% | Oppenheimer | $75 → $130 | Maintains | Outperform |
| 01/08/2021 | — | Credit Suisse | Downgrades | Neutral → Underperform | |
| 11/24/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/25/2020 | 13.3% | Credit Suisse | $13 → $42 | Maintains | Neutral |
| 08/20/2020 | 102.32% | Oppenheimer | → $75 | Initiates Coverage On | → Outperform |
| 07/27/2020 | -16.37% | Piper Sandler | $21 → $31 | Maintains | Overweight |
| 06/17/2020 | -43.35% | Piper Sandler | $18 → $21 | Maintains | Overweight |
| 05/29/2020 | -46.05% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/05/2020 | -70.33% | Credit Suisse | $12 → $11 | Maintains | Neutral |
| 11/05/2019 | -66.82% | Piper Sandler | $9.5 → $12.3 | Upgrades | Neutral → Overweight |
| 04/26/2019 | — | Credit Suisse | Downgrades | Outperform → Neutral | |
| 05/09/2018 | -86.51% | Credit Suisse | $6 → $5 | Maintains | Outperform |
| 03/01/2018 | — | Piper Sandler | Downgrades | Overweight → Neutral | |
| 03/01/2018 | -83.81% | Credit Suisse | $6.5 → $6 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/08/2022 | 7.9% | 派珀·桑德勒 | $65 → $40 | 評級下調 | 超重→中性 |
| 11/18/2022 | 21.39% | 雷蒙德·詹姆斯 | → $45 | 開始承保 | →跑贏大盤 |
| 11/14/2022 | 34.88% | 瑞士信貸 | $65 → $50 | 維護 | 跑贏大盤 |
| 11/14/2022 | 75.34% | 派珀·桑德勒 | $70 → $65 | 維護 | 超重 |
| 08/25/2022 | 75.34% | 瑞士信貸 | → $65 | 開始承保 | →跑贏大盤 |
| 05/16/2022 | 88.83% | 派珀·桑德勒 | $85 → $70 | 維護 | 超重 |
| 01/25/2022 | 237.2% | 奧本海默 | $141 → $125 | 維護 | 跑贏大盤 |
| 08/10/2021 | 75.34% | 瑞士信貸 | $55 → $65 | 維護 | 表現不佳 |
| 03/05/2021 | 277.66% | 派珀·桑德勒 | $135 → $140 | 維護 | 超重 |
| 02/01/2021 | 250.69% | 奧本海默 | $75 → $130 | 維護 | 跑贏大盤 |
| 01/08/2021 | — | 瑞士信貸 | 評級下調 | 中性→表現不佳 | |
| 11/24/2020 | — | BTIG | 評級下調 | 購買→中性 | |
| 09/25/2020 | 13.3% | 瑞士信貸 | $13 → $42 | 維護 | 中性 |
| 08/20/2020 | 102.32% | 奧本海默 | → $75 | 開始承保 | →跑贏大盤 |
| 07/27/2020 | -16.37% | 派珀·桑德勒 | $21 → $31 | 維護 | 超重 |
| 06/17/2020 | -43.35% | 派珀·桑德勒 | $18 → $21 | 維護 | 超重 |
| 05/29/2020 | -46.05% | BTIG | → $20 | 開始承保 | →購買 |
| 05/05/2020 | -70.33% | 瑞士信貸 | $12 → $11 | 維護 | 中性 |
| 11/05/2019 | -66.82% | 派珀·桑德勒 | $9.5 → $12.3 | 升級 | 中性→超重 |
| 04/26/2019 | — | 瑞士信貸 | 評級下調 | 跑贏→中性 | |
| 05/09/2018 | -86.51% | 瑞士信貸 | $6 → $5 | 維護 | 跑贏大盤 |
| 03/01/2018 | — | 派珀·桑德勒 | 評級下調 | 超重→中性 | |
| 03/01/2018 | -83.81% | 瑞士信貸 | $6.5 → $6 | 維護 | 跑贏大盤 |
What is the target price for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的目標價是多少？
The latest price target for Fulgent Genetics (NASDAQ: FLGT) was reported by Piper Sandler on December 8, 2022. The analyst firm set a price target for $40.00 expecting FLGT to rise to within 12 months (a possible 7.90% upside). 7 analyst firms have reported ratings in the last year.
派珀·桑德勒於2022年12月8日報道了富金特遺傳公司(納斯達克代碼：FLGT)的最新目標價。這家分析公司將目標價定為40.00美元，預計FLGT將在12個月內上漲至7.90%(可能上漲7.90%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Fulgent Genetics (FLGT)?
富力遺傳(Fulgent Genetics)最新的分析師評級是多少？
The latest analyst rating for Fulgent Genetics (NASDAQ: FLGT) was provided by Piper Sandler, and Fulgent Genetics downgraded their neutral rating.
納斯達克(Sequoia Capital：FLGT)的最新分析師評級是由派珀·桑德勒提供的，富力基因下調了其中性評級。
When is the next analyst rating going to be posted or updated for Fulgent Genetics (FLGT)?
Fulgent Genetics(FLGT)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulgent Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulgent Genetics was filed on December 8, 2022 so you should expect the next rating to be made available sometime around December 8, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Fulgent Genetics的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Fulgent Genetics的上一次評級是在2022年12月8日提交的，所以你應該預計下一次評級將在2023年12月8日左右提供。
Is the Analyst Rating Fulgent Genetics (FLGT) correct?
分析師對Fulgent Genetics(FLGT)的評級正確嗎？
While ratings are subjective and will change, the latest Fulgent Genetics (FLGT) rating was a downgraded with a price target of $65.00 to $40.00. The current price Fulgent Genetics (FLGT) is trading at is $37.07, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Fulgent Genetics(FLGT)評級被下調，目標價為65.00美元至40.00美元。富金特基因公司目前的股價為37.07美元，超出了分析師的預測範圍。